The Danish laboratory Novo Nordisk has announced a further price reduction for its obesity treatment Wegovy in South Africa, the second in a short period of time.
The price of the minimum dose has been significantly reduced, from approximately 3,090 rand to 1,873 rand, a substantial reduction intended to improve access to the drug.
This strategy aims to strengthen the product's competitiveness against Mounjaro, developed by Eli Lilly, which is already present on the South African market.
Novo Nordisk also plans to launch a pill version of Wegovy in the country, in order to expand its offering and reach more patients.
In parallel, the company has initiated legal proceedings against a local preparer suspected of manufacturing counterfeit versions of the drug, a phenomenon on the rise with the popularity of slimming treatments.
This price decrease comes amid strong global demand for obesity medications, but also increased pressure on laboratories to make these treatments more accessible.
The South African market is thus becoming a strategic battleground for pharmaceutical giants, who are seeking to establish themselves in a rapidly expanding segment.
Community
Comments
Comments are open, but protected against spam. Initial posts and comments containing links undergo manual review.
Be the first to comment on this article.